Cargando…

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice

Detalles Bibliográficos
Autores principales:	Schmidt, Heather‐Marie Ann, Rodolph, Michelle, Schaefer, Robin, Baggaley, Rachel, Doherty, Meg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Viewpoint
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9334859/ https://www.ncbi.nlm.nih.gov/pubmed/35903882 http://dx.doi.org/10.1002/jia2.25963

Ejemplares similares

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?
por: Parikh, Urvi M., et al.
Publicado: (2022)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
por: Pinto, Rogério M., et al.
Publicado: (2023)

Regulatory science: The need for empowering Indian innovation
por: Dinda, Amit Kumar
Publicado: (2021)

Climate crisis, health equity, and democratic governance: the need to act together
por: Krieger, Nancy
Publicado: (2020)

Providing antiretroviral therapy to all who are HIV positive: the clinical, public health and programmatic benefits of Treat All
por: Ford, Nathan, et al.
Publicado: (2018)

Workshop on Implementation Science and Digital Therapeutics for Behavioral Health
por: Lord, Sarah E, et al.
Publicado: (2021)

Considering the intersection between implementation science and COVID-19
por: Chambers, David A
Publicado: (2020)

Amplifying consumers as partners in dissemination and implementation science and practice
por: Crane, Margaret E., et al.
Publicado: (2023)

Investments in implementation science are needed to address the harms associated with the sexualized use of substances among gay, bisexual and other men who have sex with men
por: Knight, Rod
Publicado: (2018)

Getting to zero HIV deaths: progress, challenges and ways forward
por: Ford, Nathan, et al.
Publicado: (2013)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

887. Implementation of Long-acting Injectable Cabotegravir/Rilpivirine for HIV-1 Treatment at a Ryan White-funded Clinic in the U.S. South
por: Collins, Lauren F, et al.
Publicado: (2021)

Optimization Methods and Implementation Science: An Opportunity for Behavioral and Biobehavioral Interventions
por: Guastaferro, Kate, et al.
Publicado: (2021)

Cabotegravir
Publicado: (2022)

Implementation science in plain language: The use of nonjargon terms to facilitate collaboration
por: Dorsey, Shannon, et al.
Publicado: (2023)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Where Is the Implementation Science? An Opportunity to Apply Principles During the COVID-19 Pandemic
por: Taylor, Stephanie Parks, et al.
Publicado: (2020)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Contact Tracing Apps: Lessons Learned on Privacy, Autonomy, and the Need for Detailed and Thoughtful Implementation
por: Hogan, Katie, et al.
Publicado: (2021)

POCSO Act, 2012: Consensual Sex as a Matter of Tug of War Between Developmental Need and Legal Obligation for the Adolescents in India
por: Anchan, Veenashree, et al.
Publicado: (2020)

Advancing the reporting of mechanisms in implementation science: A guideline for reporting mediation analyses (AGReMA)
por: Cashin, Aidan G, et al.
Publicado: (2022)

The need to implement non-industry COVID-19 clinical trials in non-high-income countries
por: Dal-Ré, Rafael, et al.
Publicado: (2020)

Addressing vulnerabilities in communities facing infectious disease threats: A need for social science-driven assessments
por: Osborne, Jacob, et al.
Publicado: (2021)

The need for a European hepatitis C programme monitoring resistance to direct-acting antiviral agents in real life to eliminate hepatitis C
por: Popping, Stephanie, et al.
Publicado: (2018)

Universal and Ethnic-specific Considerations on Facial Rejuvenation: Where Do You Inject Your Fillers?
por: Oranges, Carlo M., et al.
Publicado: (2016)

Pre-exposure prophylaxis (PrEP) for HIV prevention among people who inject drugs: a global mapping of service delivery
por: Shaw, Graham, et al.
Publicado: (2023)

Caesarean section in women following an abdominal myomectomy: a choice or a need?
por: Odejinmi, F, et al.
Publicado: (2020)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Early Experience Implementing Long-Acting Injectable Cabotegravir/Rilpivirine for Human Immunodeficiency Virus-1 Treatment at a Ryan White-Funded Clinic in the US South
por: Collins, Lauren F, et al.
Publicado: (2022)

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
por: Letendre, Scott L, et al.
Publicado: (2020)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Containing COVID-19: Implementation of Early and Moderately Stringent Social Distancing Measures Can Prevent The Need for Large-Scale Lockdowns
por: Koh, Wee Chian, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5nid24p1eel2g7hk9pg053jsrh